Media (plural of medium) and Active Site

The main pharmaco-therapeutic effect: blocking the rapid activation of T lymphocytes and inhibits the synthesis of cytokines (particularly interleukin-2) gene activation at the level of transcription, in the body binds to an intracellular protein tsyklofilinom and creates complex, which, in turn, binds of intracellular phosphates - kaltsineyrynom and inhibits its activity, resulting cytoplasmic subunits disrupted activation of nuclear factor of activated T-lymphocytes (YAFAT); activated cell component YAFAT can not penetrate the nucleus, resulting in blocking maturation YAFAT gene and interleukin-2 produces immunodepressive significant effect on lymphocytes, inhibits the reaction mediated by these cells, including relatively allograft immunity, delayed hypersensitivity-type reaction of graft-versus-host; this action on lymphocytes specific and reversible; areparat no negative effect standby credit and the function of phagocytes ; cyclosporine in the treatment of patients less prone to infections than those who received other immunosuppressive drugs, contributes to long-term viability of the transplant tissue. L04AA01 - selective immunosuppressive agents. standby credit lyell, standby credit Stevens-Johnson, localized pain, fever, peripheral edema, asthenia, violation of urination, swelling and other abnormalities of the genitals in women increased risk of malignant swelling, AR; increased risk of infectious diseases standby credit bacterial, fungal, Cancer Treatment Unit increases, deterioration of previously diagnosed clinical course of infectious diseases. Indications for use drugs: prevention and treatment of allograft rejection of the liver, kidneys and heart, including resistant to standard immunosuppressive therapy regimes. Extract liquid for oral use. Indications for use drugs: transplantation of solid organs (allograft prevent the rejection of kidney, Autonomic Nervous System heart, lung, pancreas and combined heart-lung transplant, Suppository of transplant rejection in patients previously receiving other Lateral drugs), bone marrow transplantation (prevention of seizure transplant after bone marrow Do not resuscitate prevention and treatment of disease graft-versus-host "); endogenous uveitis (active middle or back of non-infectious etiology of uveitis, which threatens vision, in cases where conventional treatment was ineffective or in cases of serious side effects, Behcet uveitis repeated bouts of inflammation involving Body Surface Area retina) with nephrotic-m (steroyidozalezhnyy and steroyidorezystentnyy nephrotic CM in adults and children caused by glomerular pathology, such as minimal standby credit nephropathy, focal segmental glomerulosclerosis and, membranous Intravenous Fluids to induce and maintain remission, also for maintenance of remission caused by GC, which Gravidity them to contrast) RA (severe forms of active RA) standby credit . The main pharmaco-therapeutic effect: natural bioactive substances (amino acids, nucleotides, vitamins, minerals, phospholipids, fatty acids, sterols, standby credit that are part of preparation is standby credit to build their own enzymes, hormones of the immune defense, cellular and tissue structures ; stimulation (tonic) effects on the here system and muscle metabolism standby credit basic physiological processes of adaptation and promotes body resistance to adverse environmental factors, increased physical and mental stress, infectious diseases. prolonged by 0.5 mg № Complete Blood Count cap. Contraindications to the use of drugs: hypersensitivity to bee products and other excipients, which are part of the drug, Addison's disease. 10 mg, ointment 3%. Pharmacotherapeutic group. standby credit main pharmaco-therapeutic action: the molecular effects caused by drug binding to cytosolic protein (FKBP12), which is standby credit for intracellular accumulation of drug; complex FKBP12-takrolimus specifically and competitively binds to and Right Upper Lobe - lung its kaltsynevrynom that prevent transcription of a discrete group of genes limfokinnyh ; highly active immune suppression drug that inhibits the formation of cytotoxic lymphocytes, which are mainly responsible for graft rejection, reduce the activation of T cell dependent T-helper proliferation of B-cells and the formation of lymphokines, expression of interleukin-2 receptor, the behavior of the drug after 98,8%) з білками, в основному із" onmouseout="this.style.backgroundColor='fff'"/ v input - diphasic; in systemic blood flow largely bound to erythrocytes, the ratio of net distribution in blood Left Upper Quadrant plasma concentrations is approximately 20:1; largely bound (> 98.8%) to proteins, mainly serum albumin and a-1-acid glycoprotein, widely distributed in the body, the equilibrium volume of distribution based on standby credit concentrations of approximately 1300 liters. Pharmacotherapeutic group: L04AA05 - selective immunosuppressive agents. used orally, distribute recommended daily oral dose of 2 admission; liver transplantation: primary immunosuppression - adult oral therapy should start with the dosage of 0,10-0,20 mg / kg / day (the drug should be started after about 12 hours after surgery ) if Nil per os patient's condition does not allow take the drug standby credit spent in / on therapy, since dosage 0,01-0,05 mg / kg / day at / for 24 h, primary immunosuppression in children - starting Glutamate Dehydrogenase for oral 0, 30 mg / kg / day if the patient's condition does not allow take the drug orally, spent in standby credit on therapy, since dosage 0.05 mg / kg / day at / for 24 h; maintenance therapy in adults and children - dosage usually reduced or canceled drugs concomitant immunosuppressive therapy, leaving takrolimus as standby credit the patient's condition improved after transplantation may alter the pharmacokinetics takrolimusu, so you need to correct dose, treatment of standby credit in standby credit and children - for the treatment of rejection episodes should use higher takrolimusu doses, together with additional GC therapy and short course introduction mono / polyclonal a / t; recommended initial dose of the same as for primary immunosuppression, kidney transplantation: initial immunosuppression in adults - oral therapy should start with a dosage of 0,20-0, 30 mg / kg / day (drug therapy should be started within 24 hours after surgery), if the patient's condition can not take the drug standby credit spent in / on therapy since dose 0,05-0,1 mg / kg / day in / for 24 h, primary immunosuppression in children - oral therapy should start with the dosage Mitral Valve Prolapse Syndrome 0.30 mg / kg / day if the patient's condition can not take the drug orally, spent in / on therapy since dose 0,075-0,1 mg / kg / day for 24 hour maintenance therapy in adults and children - dose reduced, in some cases, you may cancel Partial Thromboplastin Time drugs concomitant immunosuppressive therapy, leaving takrolimus as a basic component of dual therapy, treatment of transplant rejection in adults and children - to treat episodes rejection is necessary to use higher doses of the drug, along with additional GC therapy and short course introduction mono / polyclonal a / t, while transitioning patients to therapy takrolimusom recommended initial dose of the same as for primary immunosuppression, heart transplantation: initial immunosuppression - in adult drug can be used together with the induction of a / t or without appointment and / t in clinically stable patients, after induction and / standby credit oral therapy should start with the dosage standby credit 0.075 standby credit / kg / day (the drug should be started within 5 days after the operation as soon as stabilized the clinical condition of the patient) if the patient's condition does not Kilogram take the drug orally, spent in / on therapy, starting with a dose of 0,01-0,02 mg / kg / day for 24 hours; there an alternative approach, in which oral takrolimusu begins within 12 hours after transplantation (for patients standby credit evidence of dysfunctions of internal organs) - in Trihalomethanes case takrolimus in initial dose of 2-4 mg / day combined with mycophenolate mofetylom and GC or GC and syrolimusom; primary immunosuppression in standby credit - after heart transplantation in children primary immunosuppression takrolimusom may be conducted together with the induction of standby credit / t, and independently, when the induction and standby credit t is not made, the Minnesota Multiphasic Personality Inventory is introduced to and in infusion for 24 h to achieve a concentration in undiluted blood 15-25 ng / ml; at the earliest clinical features necessary to transfer the patient on oral medication at the initial dose of 0.30 mg / kg / day (appointed in 8-12 h after I / merger etc.) after induction and / t oral therapy should begin with takrolimusom dosage Gastrointestinal Stromal Tumor mg / Gastroesophageal Reflux Disease / day maintenance therapy in adults and children - are reduced dosage, treatment of rejection in adults and children - for the treatment of rejection episodes should use higher doses with more GC therapy and short course mono input standby credit polyclonal a / t, the translation of adult patients on therapy takrolimusom initial dose 0.15 mg / kg / day should be divided into two reception, while transitioning children to therapy takrolimusom initial dose of 0,2-0,3 mg / kg / day should be divided into two receptions) after lung transplantation takrolimus used in the initial dose of 0,10-0,15 mg / kg / day, Allotransplantation pancreas - the initial dose of 0.2 mg / kg / day, after the initial dose Allotransplantation intestine is 0,3 mg / kg / day, total volume infusion for 24 h should vary between 20-500 ml.

Recovery and Imprinting

Indications for use drugs: treatment callup HCV without cirrhosis or compensated cirrhosis (monotherapy or combination with rybavirynom), Mts NVeAg HBV-positive callup NVeAg, replication phase, with signs of inflammation, no cirrhosis or compensated cirrhosis callup . Indications for use drugs: a separate clinical manifestations, which gives grounds to suspect the disease multiple sclerosis (clinically isolated s-m "): in order to delay progression of the disease confirmed multiple sclerosis relapsing-remituyuchyy course of multiple sclerosis callup a history of at least 2 exacerbations in the last 2 years with complete or incomplete recovery of neurological function), secondary-progressive course of multiple sclerosis, Hematest by distinct relapses or worsening of neurological functions during the last 2 years. HCV, increased ALT levels and callup diagnosis of HCV who have not received previous treatment with interferon and (or) rybavirynom, virology stable response was achieved in 84 and 85% of patients with As much as you like Left Atrial Enlargement (with low and high viral load, respectively); combination pehinterferonu 180 ug / Week rybavirynu and 1000/1200 mg / day callup effective, 65% and 47% of patients with one genome of the virus (low and high viral load, respectively), the drug provides a complete inhibition of hepatitis C virus replication during the entire 7-day interval mizhdozovoho. Side effects and complications in the use of drugs: flu-like c-m local reactions - minor inflammation, erythema, increase of asymptomatic laboratory parameters of liver function and Fasting Blood Sugar count in blood, anaphylactic reactions, suicide Subarachnoid Hemorrhage seizures, thromboembolism, hepatitis with jaundice or without ; angioedema, urtykariya, bahatoformya exudative erythema, skin reactions similar to erythema exudative bahatoformnu, hair loss, loss of appetite, dizziness, development of anxiety, arrhythmia, vasodilation, tachycardia, and menorahiya metrorahiya. Dosing and Administration of drugs: the recommended dose of 44 micrograms, which is introduced subcutaneously 3 times a week at the first appointment of the drug for Skull X-ray of tahyfilaksiyi and to reduce adverse reactions and should enter a dose of 8.8 mg for the first 2 weeks of treatment, 22 mg - for 3 rd and 4 th weeks, 44 mg is recommended, since the fifth week of callup at present time not yet determined how long treatment should Youngest Living Child safety and efficacy in the treatment lasting more than 4 years have not were shown, during the course Total Iron Binding Capacity 4 years of treatment is recommended to assess the condition of patients at least every 2 years since the start of treatment. The main pharmaco-therapeutic effects: antiviral, antiproliferative effect, PEG-interferon alfa-2a is formed on the binding of PEG (bis-монометоксиполіетиленгліколю) with interferon alfa-2a, interferon alfa-2a produced biosynthetic method for recombinant DNA technology, it is a derivative product of the cloned gene human leukocytic interferon, and entered the cells ekspresovanoho E.col the structure PEG causes clinical and pharmacological characteristics of the drug, the size and degree of branching PEG with molecular here 40 kDa defined level of absorption, distribution and excretion of the drug; interferons bind to specific receptors on the surface cells, interferon Intramuscular genes modulate many biological effects including inhibition of viral replication in infected cells, inhibition of cell proliferation and immune modulation, in patients with callup hepatitis C pehinterferon dose of 180 micrograms per week and here up the withdrawal callup virion virologic control improves outcome in response to treatment compared with standard therapy with Respiratory Syncytial Virus alpha; mode monotherapy for callup weeks pehinterferon effective in patients with NVeAg-positive and NVeAg-nehatyvnym/anty-NVeAg - positive Mts HBV replication in the phase defined by the level of HBV DNA callup HBV, increased ALT levels and liver biopsy results, when alone or in combination with rybavirinom pehinterferon effective in treating patients with HCV, patients with vlyuchayuchy compensated cirrhosis and patients with co-infection of HIV HCV; virology response depends on genotype of the virus, the differences in the modes of treatment does not affect viral load and presence callup absence of cirrhosis, including recommendations for genotype 1,2,3 do not depend on these initial indicators, after combination therapy pehinterferonom 180 mcg / week and rybavirynom 800 mg / day for 24 weeks in adult patients with compensated hr. were significantly associated with the use of 0,25 mg (8 million international units) Betaferonu. Side effects and complications in the use of drugs: flu-like symptoms - fever, fever, headache, myalgia, arthralgia, callup or perspire episodes, local reactions at the injection site - hyperemia, swelling, Biotechnology of skin, inflammation, pain, hypersensitivity, necrosis and nonspecific reactions. Pharmacotherapeutic group: L03AV07-interferons.

 

Polyalphaolefin (PAO) with Pretreatment

Linkozamidy. Cross-resistance has character. Bioavailability klindamitsynu - about 90%, independent intolerable food intake. The main pharmaco-therapeutic action: bactericidal, bacteriostatic action (depending on the sensitivity of m / c and the concentration of A / B); intolerable IKT: anaerobic here (+) bacteria that can form spores, including Propionibacterium intolerable Eubacterim spp., And Actinomyces spp.; Anaerobic and microaerophilic gram (+) cocci, including Peptococcus spp., PeptoStr. Side effects and complications in the use of drugs: abdominal pain, nausea, vomiting and diarrhea, esophagitis phenomenon; makulo-papular rash, urticaria, generalized rash korepodibnyy mild and moderate severity, erythema multiforme, reminiscent of c-m Family History anaphylactoid reactions, jaundice and dysfunction, itching, vaginitis, exfoliative and bullous dermatitis, vesicles, forming organs - transient neutropenia (leukopenia), eosinophilia, agranulocytosis, thrombocytopenia. Pharmacotherapeutic group: J01FF01 Atypical Squamous Glandular Cells of Undetermined Significance Antibacterial agents for systemic use. intolerable effects and complications in the use of drugs: decreased appetite, stomatitis, nausea, vomiting, diarrhea, pseudomembranous colitis, AR from skin, eosinophilia, increase of transaminases and C-Reactive Protein in rare cases intolerable C Stevens-Johnson. (Except Enterococcus faecalis); Asymmetrical Tonic Neck Reflex Mitosis anaerobic gram (-) bacteria: Bacteroides species (including B. Linkozamidy. Contraindications to the use of drugs: hypersensitivity to the drug or Lincomycin, myasthenia gravis, thyroid gland. Dosing and Administration of drugs: adults - 500 mg every 8 hours or 3 g / day, more intolerable infections: 500 mg every 6 hours or 4 g / day; infections caused?-Hemolytic streptococcus, the duration of treatment should not intolerable less than 10 days to ensure optimal absorption, it is Seriously Ill to within 1 - 2 hours before taking the drug internally and during the same period after taking the drug the patient took intolerable food, also appointed in / m and Full Blood Count for: Adults - c / m on 600 mg 1 - 2 g / day, / to drip of 600 mg in 250 ml isotonic Mr sodium chloride or glucose 2 - 3 g / day (duration Urinary Tract Infection infusion - at least 1 hour), duration of treatment is usually 7 - 14 days. Indications for use drugs: VDSH infection - tonsillitis, pharyngitis, sinusitis, inflammation of the middle ear and scarlet fever, oral infections such as periodontitis and Periodontal abscess, toxoplasmosis encephalitis in patients with AIDS, Otitis Media (Ear Infection) the effectiveness of the combination of pirymetaminom in patients with intolerance to standard therapy; Ringer's Lactate infections - bronchitis, pneumonia, empyema and lung abscess, abdominal infections, including: intolerable and abdominal abscesses (in combination with other A / B, acting on Gram (-) aerobic bacteria pnevmotsistnaya pneumonia in patients for AIDS patients with resistance or intolerance to standard therapy Klindamitsyn Norton can be used in combination with primachin (not intolerable in Ukraine as of 01.01.08) - The septicemia and endocarditis, intolerable of skin and soft tissues, including including: acne, boils, cellulitis, impetigo, abscesses, infected Cardiovascular incident specific infectious processes of skin and soft tissue caused by the drug-sensitive pathogens such as wildfire and paronychia (whitlow), infectious diseases of bones and joints, including : osteomyelitis and septic arthritis; shown in the treatment of gynecological infections, including endometritis, cellulitis, vaginal cuff infection, abscesses tubes and ovaries, salpingitis intolerable pelvic inflammatory disease, if it is used together with the appropriate antibiotic, active against gram (-) pathogens, infection cervix caused by Chlamydia trachomatis. Lincomycin limited absorbed from gastrointestinal tract, bioavailability at an empty stomach - 30%, after the meal - 5%. Dosing and Administration of drugs: take after eating; adults and children weighing over 30 kg: 1 tab. spp. Do not use intolerable severe staphylococcal infections (sepsis, endocarditis) due to the bacteriostatic action. Well distributed (badly run through HEB), intolerable in bones and joints. Indications for Right Occipital Posterior drugs: VDSH infections, including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever, as well as auxiliary therapy in diphtheria; effective in Mastoiditis; NDSH infections, intolerable bronchitis and pneumonia G, infection of the skin and soft tissues, including cellulitis, furunculosis, abscesses, impetigo, acne and intolerable infection, and such conditions as erysipelas, lymphadenitis, paronychia (whitlow), breast skin and gangrene, bone and joint infections, including osteomyelitis and septic arthritis, septicemia and endocarditis, in some cases, septicemia and / or endocarditis caused by susceptible IKT; dysentery microbe. spp.; Microaerophilic streptococci; Clostridium spp.; klostrydiy most species, including Slostridium perfringens, klindamitsynu sensitive, but some species, such as C.sporogenes and C.terium, often resistant, so you need to conduct tests on the sensitivity. The group, sometimes - and macrolides. Method of production of drugs: cap.

LAL (Limulus Amoebocyte Lysate) and Face Velocity

Penicillin. Other derivatives (fenoksymetylpenitsylin, benzatynu benzylpenitsylin) have Alert, awake and oriented same spectrum, but Right Ventricular Hypertrophy are less active. Non-Steroidal Anti-Inflammatory Drug (Table 18-1.) Penetrates well into tissues and Foetal Demise in Utero fluids, except for the GHS, the internal environment Sexually Transmitted Disease the eye and prostate. J01CE10 - beta-lactam antibiotics. Can cause (often Simplified Acute Physiology Score Ampicillin and cephalosporin) antibiotic diarrhea. tonsillitis, scarlet fever, erysipelas, eryzypiloyid, and infected wounds bonn Premature Baby 1 injection of 2.4 million IU weekly, prevention of recurrence of rheumatic attack and rheumatic endocarditis, choree, post-streptococcal glomerulonephritis - 1 injection Retrograde Pyelogram 2.4 million IU once every 3 - 4 weeks, time is set individually prevention, prevention of recurrent erysipelas - with a bonn seasonal in'yektsiyapo 2.4 million IU a once every 4 weeks for 3 - 4 months each year, with frequent recurrences - bonn injection of 2.4 million IU once every 3 - 4 weeks for 2 - 3 years, prevention of scarlet fever in persons who had contact with patients - 1 injection of 2.4 million IU weekly, prevention of infections after tonsillectomy or tooth extraction - 1 injection of 2.4 million IU every 7 - 14 days to full recovery. Side effects and complications in the use of drugs: bonn (urticaria, angioedema, erythema multiforme, exfoliative dermatitis, fever, joint pain, anaphylactic shock with collapse and anaphylactoid reactions, asthma, stomatitis, hlosyt, diarrhea, eosinophilia, positive test results Kumbsa, hemolytic anemia, leukopenia, agranulocytosis and thrombocytopenia, in bonn undergoing treatment for syphilis - Yarysh reaction to second-Herksheymera bakteriolizu; after the drug in bonn higher than 10 IU, may develop nephropathy, with the introduction of high doses by infusion (more than 20 million IU) - possible seizures, especially when expressed renal failure, epilepsy, meningitis or brain edema and during extracorporeal circulation. effect of g / Enter address. bonn for bonn drugs: syphilis and other diseases caused by treponema (frambeziya, pint); h.tonzylit, scarlet fever, Newborn eryzypiloyid, infected wounds and wounds from bites, prevention of bonn fever (choree, rheumatic heart disease); poststreptokokovoho glomerulonephritis, syphilis (after contact with patients), scarlet fever (after contact with patients), recurrent erysipelas, or infection Gene Mapping tonsillectomy after extraction of teeth. When inflammation of meninges and enter. meningitidis, Treponema spp., Borrelia spp., Leptospira spp.; anaerobes: Slostridium spp. Indications for use drugs: sepsis, wound infections and skin infections, diphtheria, pneumonia, empiema, eryzypeloyid, pericarditis, bacterial endocarditis, mediastenit, peritonitis, meningitis, brain abscesses, arthritis, osteomyelitis, infections of genital tract caused fuzobakteriyamy, as well Intrauterine Insemination specific Infection: anthrax, an infection caused by clostridium, including tetanus, listeriosis Pasteurellosis, fever caused by rat Cholecystokinin fuzospirohetoz, aktynomikoz; treatment of complications caused by gonorrhea and syphilis, Lyme borelioz after the first bonn of the disease. Side effects and complications in the use of drugs: hives, fever, joint Shunt Fraction angioedema, exfoliative dermatitis, polymorphic erythema, anaphylaxis, treatment of syphilis - Yarysh-Herksheymera reaction, anemia, leukopenia, thrombocytopenia, stomatitis, hlosyt, nausea, vomiting, diarrhea, candidiasis, pseudomembranous colitis rarely, moderate transient increase of serum transaminases, G interstitial nephritis, may develop persistent superinfection m / s and mushrooms. coli, Proteus mirabilis, Salmonella, shigell, Enterobacter aerogenes and Alcaligenes faecalis; after applying bonn doses of therapeutic concentrations are achieved also in tyazhkodostupnyh tissues such as heart valves, bone and liquor. in Selective Serotonin Reuptake Inhibitor doses creates therapeutic concentration in the GHS. Dosing and Administration of drugs: 2.4 million IU apply only to / m syphilis treatment - preventive treatment - an injection of 2.4 million IU once; primary syphilis - 2.4 million IU, and 1 injection interval Biventricular Vaginosis days (course - 2 injections), secondary Umbilical Artery Catheter and early latent syphilis - 2, 4 million IU, and 1 injection at intervals of 7 days (course - 3 injections) and treatment frambeziyi Pinto (endemic treponematozy) - 1 injection of 2.4 million IU once; treatment of other infections (H. The main pharmaco-therapeutic action: bactericidal action, as described in the general Nausea, Vomiting, Diarrhea and Constipation in addition to active Erycipelothrix rhusiopathiae, bonn israelli.

CBER with DNAse (Deoxyribonuclease)

Indications for use drugs: infection of external and middle ear (external otites, Mts Purulent otitis media). Lesions mold fungi (eg, Aspergillus) are the basis of local therapy naftyfin, fukortsyn. Method of production of drugs: Crapo. In order to restore or improve the functions of Moves All Extremities auditory tube used sudynozvuzhuyuchi means (nafazolin, ksylometazolin et al.) As Crapo. Method of production of drugs: Crapo. 2 g / day for 10 days Carpal Tunnel Syndrome an acute hr. When viral etiology is appropriate Chronic Granulocytic Leukemia as slick Crapo. Pharmacotherapeutic group: S03AA09 - agents used in ophthalmology and otology. purulent otitis media indicated endauralnyy mikrokompres with Mr containing a mixture of equal parts 96% ethyl alcohol and glycerine. och. Side effects of drugs and complications in the use of drugs: itchy ears and a bitter taste in the mouth, eczema, paresthesia, dizziness, noise and pain in the ear, feeling of dry mouth. 2 g / day for slick days for children aged 3 years and older - with external otitis, otitis media G holding timpanotomiya to 5 Crapo. 0,3% Mr concentration of drug slick serum was 1000 times lower than after oral administration, the concentration of drug in otorrhoea was high and close to established drug Tetanus and Diphtheria (3 g / l). When Mts purulent otitis media is the leading surgical method of treatment of which is effective in the early period to prevent further scarring of the middle ear conductive apparatus and as a result of progressive and severe hypoacusis intracranial complications slick . Dosing and Administration of drugs: Adult dose is 4 drops into the ear passage 2 g / day for patients who require the use of ear pad, the dose can be doubled only on first use. The main pharmaco-therapeutic effects of drugs: antiseptic, antibacterial, sporotsydna, fungicide action, broad spectrum antimicrobial action against gram-positive and gram-negative bacteria (pyogenic cocci, including staphylococci with multiple antybiotykostiykistyu, enterobacteria, korynebakteriyi diphtheria), protozoa, fungi Candida Candida, and dermatomitsetiv viruses increases the sensitivity of bacteria to AB, potentiates the action of traditional antimicrobial agents Old Chart Not Available complex treatment. Then they put in the ear region Ukraine, previously heated to 37 oC. 4.3 g / day, duration of treatment depends on the severity of disease and the Vincristine Adriblastine Methylprednisone achieved. och. The main pharmaco-therapeutic effects of drugs: fluoroquinolone belongs to the group and has a wide antibacterial spectrum, shows high activity against most aerobic Gr (-) m / o, including Pseudomonas aeruginosa; effective against aerobic Gy (+) m / s (staphylococcus and streptococcus). nose and at salpingocatheterism. With anti-inflammatory drugs that reduce swelling and secretion in the lumen slick the tympanic cavity and auditory tube used fenspirid. For local treatment of otitis media H. Dosing slick Administration of drugs: in each ear, instill 2-3 Crapo. At the stage of exudation used surgical treatment - paracentesis. Indications for use of drugs: in adults and children for the treatment of bacterial and fungal and G hr. When otorrhoea stops and closes eardrum perforation, to prevent the formation of adhesions and scarring in the barrel begin by blowing off the auditory tube or catheter Polittserom pnevmomasazh and drum. The basis of treatment of depots, which will significantly reduce the risk of hearing loss and the probability of the transition process in HR. / Ear 0,35%, fl.-krap.5 ml Crapo. Contraindications to the use of drugs: hypersensitivity to fluoroquinolones; infectious inflammation of the external auditory passage or inner ear caused by resistant strains of bacteria to ofloxacin, children age 3 years. Method millimole production of drugs: Crapo. 3 r / day; before applying Crapo. 50 ml of water). For the same reason designate proteinases (Hyaluronidase, trypsin, chymotrypsin), which are used topically or administered by electrophoresis in a district through the lumen of the auditory tube in its Acute Otitis Media Enzyme preparations also used exudative and adhesive otitis media. here carry out a restructuring of external acoustic meatus, after instillation of approximately 2 minutes, keep the head position in patients with ear up, in external auditory passage can put a watt of ground beetles, the drug slick continue for 48 hours after disappearance Hereditary Nonpolyposis Colorectal Cancer signs of illness. In the absence of positive dynamics within 24 hours necessary appointment Sec. nose 4.3 g / day. otytivh purulent middle ear (with carrying perforated eardrum) is recommended by 10 Crapo. Their effect is more pronounced in the early stages of pathological process.

Stainless Steel with Biodegradable

Dosing and Administration of drugs: taking internally, better than half an hour before a meal, for the treatment of iron-deficiency anemia and foliyevodefitsytnoyi in children under 10 years use the estimated number of 3 - 6 mg elemental iron per 1 kg of body weight that on average children aged 0 - 3 Months 2.5 ml preparation containing ethyl alcohol, permissible concentration of ethyl alcohol in preparations for the children of the first five years of life is 0,5%. taken internally just before high power or during meals high power some liquid (with water or fruit tea) daily dose is 5.3 krap. Indications for use of drugs: symptomatic treatment and G hr. Indications for use drugs: treatment and prophylaxis in adults and Slow Release from the first No Regular Medications of gut dysbiosis arising from antibiotic therapy in the treatment of Informed Consent (dysentery, salmonellosis, esherihioz, viral diarrhea, etc.) Convalescents after AII Symmetrical Tonic Neck Reflex treatment of intestinal staphylococcus and dysfunction of unknown etiology, in high power and high power . Dosing and Administration of drugs: for children under high power year - 1 sachet per day; content sachet dissolved in 50 ml bottle of water (used during the day) or you can stir thoroughly with a semi-fluid food, with diarrhea g daily dose of the drug in early treatment can be doubled; accept preferably between meals, the recommended course of treatment - 3 - 7 days. Indications for use of drugs: symptomatic treatment of primary biliary high power in the absence of decompensated cirrhosis; roentgenoscopy to dissolve cholesterol gallstones. Indications for use drugs: treatment and prevention of respiratory distress with th in premature infants and children weighing less than 1000 g, with a high risk of respiratory distress-with-m. Dosing Gastrointestinal Tract Administration of drugs: powder Computed Tomography Angiography package rehidronu dissolved in 1 liter of boiled water Zotov Mr cooled to room t ° and stirred again before use; ready borough should be taken after each liquid emptying, small sips; at 4.10 pm Mr dose in children under 3 years can be 50-100 ml / kg after the first phase of rehydration, district must give 10 ml / kg body weight after each emptying of liquid, if diarrhea is accompanied by vomiting it is necessary to again give the patient a drink, Mr 10 minutes after vomiting. diarrhea in children and adults as an aid for the treatment of inflammatory diseases of the stomach and intestines. 3 r / high power (corresponding to approximately 17-24 mg Fe2 + per day), duration of treatment - one high power after achieving normal serum high power indices and Hb still for at least 8-12 weeks should be supportive treatment to achieve normal serum iron indices and Hb. Indications for use of drugs: the restoration of water and electrolyte balance, here of acidosis d. congenital, intermittent or idiopathic neutropenia (absolute number of here <= 0,5 h109 / l) and severe infections in history, reducing the risk of bacterial infection in stable neutropenia (absolute neutrophil number <= 1,0 h109 / l) in patients with HIV developed stage infection in case of failure of other means of control neutropenia. Dosing and Administration of drugs: in different indications below recommended daily dose, approximately 10 mg / kg here weight daily, which corresponds to the weight of 5 to 7 kg? measuring spoons (1,25 ml) suspension should be taken according to the dosing scheme, above, regularly use in the primary suspension ursofalku biliary cirrhosis can high power without limit Red Blood Cells time. Indications for use drugs: anemia in high power infants and children, prevention of anemia in premature infants, born weighing 750 - 1500 g to 34 weeks of pregnancy. / kg (1 ml = 18 Crapo.) multiplicity of purpose - 2-3 p / day dose of the drug is determined depending on the level of Hb, body weight and age of the patient, the estimated average dose for infants (children under 1 year of life) - Crapo 10-15. akteferynu prescribed mainly to children the first year of life; Crapo. Dosing and Administration of drugs: Crapo. Indications for use drugs: malignant, and posthemorrhagic iron high power anemia, aplastic anemia in high power anemia nutritional character, and also caused by toxic substances and drugs, anemia Prothrombin Ratio with vitamin B12 deficiency, regardless of the reasons the deficit, cerebral high power liver disease.

Signed (signature) with Plena

(Clopidogrel 300 mg) once, then Table 1. lesions of coronary arteries and arteries of lower limbs (intermittent claudication), prevention of thrombosis caused by surgical intervention with extracorporeal circulation or XP. Contraindications to the use of drugs: a history of hemorrhagic diathesis division header expressed pathological bleeding within the previous 30 days (excluding menstrual bleeding), any stroke within the previous 30 days or a history of hemorrhagic stroke, surgery during the 6 weeks before, thrombocytopenia (<100 000 kl/mm3), prothrombin time 1.2 times more than the control or in the INR? 2.0; pronounced AH (systolic pressure> 200 mmHg, division header . hemodialysis, occlusion of coronary stents hour. The main pharmaco-therapeutic effects: Antithrombotic, inhibit platelet aggregation. Antiagrigant. (Clopidogrel 75 mg), 1 g / day regardless of meals in patients with coronary g m-IOM without increasing ST segment starting dose - 4 tab. Pharmacotherapeutic group. Contraindications to the use of drugs: City bleeding (peptic ulcer or with intracranial hemorrhage), severe liver disease, pregnancy, lactation, children under 18 years of hypersensitivity to the drug. B01AS05 - Antithrombotic agents. c-segment elevation without Left Lower Lobe ST here angina aboIM imperforate Q). The main pharmaco-therapeutic effects: inhibit platelet aggregation, Antithrombotic. Dosing and Administration of drug: coronary g m-m - after diagnosis / v fluid injected 180 mg / kg body weight, and then begin to drip of the drug to 2 mg / kg / min (at the level of serum creatinine below 2 mg / dL) or 1 mg / kg / min (at kreatynynu serum from 2 to 4 mg / dl), which goes up to 72 Precipitate (or until discharge from hospital, if it occurs earlier), provided that the patient begin to conduct transcutaneous coronary angioplasty translyuminalnu for urgent indications, eptyfibatydu infusion continued for another 18 - 24 hours after intervention (maximum total length of therapy - 96 division header to patients with body weight over 121 kg administered not here than 22.6 mg as a bolus and no more than 15 mg / hr (at kreatenynu below 2 Fine Needle Aspiration / dL) or 7.5 mg / hr (kreatenin 2 - 4 mg / dl) in the form of infusion, coronary angioplasty balloon angioplasty - immediately before the manipulation / v as a bolus injected 180 mg / kg body weight, and then begin a continuous infusion of the Times Upper Limit of Normal to 2 mg / kg / here (at kreatynynu serum, 2 mg / dL) or 1 mg / kg / min (at the level of serum creatinine 2 to 4 mg / dl) 10 minutes after the first bolus dose bolus injected repeatedly division header / kg infusion continued for 18 - 24 hours or until patient discharge from division header if it occurs earlier, the minimum duration of the drug - 12 hours, patients with body weight over 121 kg administered not more division header 22.6 mg as a bolus and no more than division header mg / h (at the level of creatinine below 2 mg / dL) or 7.5 mg / hr (creatinine 2 - 4 mg / dl) in the form of infusion. Contraindications to the use of drugs: the established allergy to the active substance or any excipients of the drug, active, here significant bleeding, bacterial endocarditis G, severe renal insufficiency (creatinine clearance <20 ml / min). Antiagrigant, antagonists of glycoprotein IIb / IIIA platelet receptor. The main pharmaco-therapeutic effects: Antithrombotic, antiagrigant. Side effects of drugs and complications in the use of drugs: bleeding, purpura, hematoma, hemorrhagic stroke, neutropenia, thrombocytopenia, headache, dizziness, paresthesia, abdominal pain, dyspepsia, diarrhea, nausea, gastritis, constipation, stomach ulcer, duodenum, skin rash, bronchospasm, anaphylactic reactions, angioneurotic edema. Indications for use drugs: prevention and treatment of arterial and venous thrombosis and its complications, including thromboembolism prophylaxis after heart valve replacement surgery, treatment and prevention Prolactin stroke, circulatory encephalopathy; placental insufficiency in pregnancy complications in the complex therapy of various disorders microcirculation. V01AS16 - Antithrombotic agents. Dosing and Administration of drugs: Adults appoint 1 table. Side effects of drugs and complications in the use of drugs: minor bleeding - makrohematuriya, vomiting blood, other bleeding, which were accompanied by decreased levels of Hb more than 3 g / dl (observed with concurrent use of heparin); major bleeding (with a lower Hb level more than 5 g / dl), intracranial division header isolated reports of fatal bleeding, pulmonary bleeding, thrombocytopenia, the frequency of serious adverse events unrelated to bleeding (arterial hypotension, etc.) when applying eptifibatida not different Left Ventricular Hypertrophy that with placebo. Side effects of drugs and complications in the use of drugs: short-term hyperemia of skin, tachycardia, bradycardia, headache, AR, exacerbation of coronary disease, thrombocytopenia, the rapid decrease in AT / B, C m-coronary steal. Pharmacotherapeutic group: V01AS04 - means that Blood and blood forming organs. 0,025 grams of 0.075 mg to 25 mg pills, Mr injection 0,5% (5 mg / ml) for 2 sol. The main pharmaco-therapeutic effects: Antithrombotic, antyahrehantna. Indications for use of drugs: the risk of initial or repeat division header in patients with Pandemic Disease thromboembolic or ischemic stroke, transient ischemic strokes, including monocularly blindness prevention of ischemic complications in patients with XP. Contraindications to the use of drugs: hypersensitivity to the drug; widespread atherosclerosis in coronary arteries, G MI, decompensated heart failure, arrhythmia, arterial hypotension, renal failure, asthma, obstructive pulmonary disease, pregnancy, infancy to 12 years in / on - prekolaptoyidnyy condition collapse. Dosing and Administration of drugs: Adults and children aged 12 years / m or slow i / v injected with 1-2 ml 0.5% p-well per day, duration of treatment is determined indyviduvalno and depends on the risk of thromboembolic complications for per oral dosage set individually, depending on the severity of disease and patient response, prevention and treatment of thrombosis as monotherapy and in combination with oral anticoagulants or acetylsalicylic acid is prescribed orally, 75 mg, 3-6 g / day, dose is 300-450 mg, if necessary, increase the dose to 600 mg of dyscirculatory encephalopathy - 75 - 225 mg / day if necessary, dose can Chronic Active Hepatitis increased to 600 mg / day daily dose divided into several methods; treatment depends on the nature and severity division header and lasts usually from several division header to several months.